Circulating Tumor Cell PD-L1 and Peripheral Blood CD8<sup>+</sup> T-Cell PD-1 as Dual Liquid Biopsy Biomarkers for Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer: A Retrospective Study.

Cancer Manag Res · 2026 · PMC13005986 · PMID 41873417

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Other baseline characteristics including age, gender, smoking status, and baseline metastatic burden did not reach statistical significance in the multivariate model ( Table 4 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Circulating Tumor Cell PD-L1 and Peripheral Blood CD8&lt;sup&gt;+&lt;/sup&gt; T-Cell PD-1 as Dual Liquid Biopsy Biomarkers for Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer: A Retrospective Study.

The sentences

Circulating Tumor Cell PD-L1 and Peripheral Blood CD8<sup>+</sup> T-Cell PD-1 as Dual Liquid Biopsy Biomarkers for Immunotherapy Outcomes in Advanced Non-Small Cell Lung Cancer: A Retrospective Study.